46887615_2_Diabetes_Therapy_if_Approved__5
[0] Sulfonylureas [1] Glyburide, Glipizide, Glymeperide [2] Stimulate pancreatic insulin release [3] Inexpensive, good formulary coverage [4] Hypoglycemia a major concern, weight gain, benefit tends to wane with sustained use [5] 
Hypoglycemia risks limit use, and the lack of durability of hypoglycemic response makes it suboptimal.
Where Will Invokana (canagliflozin) Fit in Type 2 Diabetes Therapy if Approved
5